Today, I have another controversial prediction. One which I will take no pleasure in seeing come true. See, even with President Trump returning as the leader of our free country, I believe Elon Musk is in mortal danger.

I share with you in this special investigative documentary.

Julie L. Gerberding net worth and biography

Julie Gerberding Biography and Net Worth

EVP of Merck & Co., Inc.

Dr. Julie Gerberding is the executive vice president and chief patient officer at Merck, a multinational pharmaceutical company.

In 2010, Dr. Gerberding joined Merck as the company’s president of vaccines, where she played a significant role in increasing worldwide access to the company’s vaccines. During her time with Merck Dr. Gerberding has built on her passions for addressing disparities within the medical community and advocating for gender parity and advancement of women in the life sciences. She is an executive sponsor of the Merck Women’s Network, mentoring dozens of women inside and outside the company. Additionally, she’s working to improve the rates of maternal mortality through the Merck for Mothers program.

Prior to joining Merck, Dr. Gerberding worked for the U.S. Centers for Disease Control and Prevention (CDC), serving as its director from 2002 to 2009. She was the first woman to hold the position. While there, Dr. Gerberding notably led the country through the anthrax crisis, SARS, bird flu, and 40 other emergency responses. From 1998 to 2002, she worked as the CDC’s divisional director for healthcare quality promotion.

Before her time at the CDC, Dr. Gerberding was a tenured faculty member in infectious diseases at the University of California, San Francisco—an institution she continues to serve to this day as an adjunct associate clinical professor of medicine. During her time in San Francisco, Dr. Gerberding served on the front lines of the city’s emerging AIDS/HIV crisis. She directed the Prevention Epicenter, which focused on preventing infection in patients and their healthcare providers.

Dr. Gerberding serves on a number of committees and boards, including the boards of Cerner Corporation, MSD, CWRU, Wellcome Trust Hilleman Laboratories, and the BIO Executive Committee.

She has received numerous awards and honors for her contributions to the medical community, from being named on Time’s list of “100 Most Influential People” in 2004, to receiving the Healthcare Businesswomen Association’s Woman of the Year award in 2018.

Dr. Gerberding earned both her undergraduate degree and her M.D. at Case Western Reserve University. She also holds her master’s of public health from the University of California, Berkeley, and completed her internship and residency in internal medicine as well as a fellowship in clinical pharmacology and infectious diseases at the University of California, San Francisco.

What is Julie L. Gerberding's net worth?: The estimated net worth of Julie L. Gerberding is at least $6.16 million as of July 17th, 2020. Dr. Gerberding owns 62,862 shares of Merck & Co., Inc. stock worth more than $6,163,619 as of December 21st. This net worth evaluation does not reflect any other assets that Dr. Gerberding may own. Learn More about Julie L. Gerberding's net worth.
How do I contact Julie L. Gerberding?: The corporate mailing address for Dr. Gerberding and other Merck & Co., Inc. executives is 2000 GALLOPING HILL ROAD, KENILWORTH NJ, 07033. Merck & Co., Inc. can also be reached via phone at (908) 740-4000 and via email at [email protected]. Learn More on Julie L. Gerberding's contact information.
Has Julie L. Gerberding been buying or selling shares of Merck & Co., Inc.?: Julie L. Gerberding has not been actively trading shares of Merck & Co., Inc. in the last ninety days. Most recently, Julie L. Gerberding sold 36,285 shares of the business's stock in a transaction on Friday, July 17th. The shares were sold at an average price of $80.00, for a transaction totalling $2,902,800.00. Following the completion of the sale, the executive vice president now directly owns 62,862 shares of the company's stock, valued at $5,028,960. Learn More on Julie L. Gerberding's trading history.
Who are Merck & Co., Inc.'s active insiders?: Merck & Co., Inc.'s insider roster includes Sanat Chattopadhyay (Insider), Frank Clyburn (EVP), Robert Davis (CFO), Richard Deluca (EVP), Kenneth Frazier (Insider), Julie Gerberding (EVP), Clark Golestani (EVP), Michael Holston (EVP), Rita Karachun (VP), Caroline Litchfield (CFO), Steven Mizell (EVP), Johannes Oosthuizen (Insider), Joseph Romanelli (Insider), Ashley Watson (SVP), and Wendell Weeks (Director). Learn More on Merck & Co., Inc.'s active insiders.
Are insiders buying or selling shares of Merck & Co., Inc.?: During the last year, insiders at the sold shares 2 times. They sold a total of 51,694 shares worth more than $6,545,285.10. The most recent insider tranaction occured on February, 13th when insider Joseph Romanelli sold 1,000 shares worth more than $124,890.00. Insiders at Merck & Co., Inc. own 0.1% of the company. Learn More about insider trades at Merck & Co., Inc..
Information on this page was last updated on 2/13/2024.

Julie L. Gerberding Insider Trading History at Merck & Co., Inc.

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
7/17/2020	Sell	36,285	$80.00	$2,902,800.00	62,862
1/13/2020	Sell	102,073	$89.34	$9,119,201.82	106,099
11/7/2018	Sell	36,218	$75.14	$2,721,420.52	82,481
5/15/2018	Sell	9,972	$59.66	$594,929.52
11/7/2016	Sell	85,523	$60.02	$5,133,090.46	77,762
5/8/2015	Sell	38,368	$60.99	$2,340,064.32

Julie L. Gerberding Buying and Selling Activity at Merck & Co., Inc.

Merck & Co., Inc. Company Overview

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. The company serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians, wholesalers, government entities, veterinarians, distributors, animal producers, farmers, and pet owners. It has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates, which include patritumab deruxtecan, ifinatamab deruxtecan, and raludotatug deruxtecan for the treatment of multiple solid tumors both as monotherapy and/or in combination with other treatments; and AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types, and Koselugo for multiple indications. The company also has a collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.

Today's Range

Now: $98.05

$97.90

$99.68

50 Day Range

MA: $102.25

$96.30

$111.54

2 Week Range

Now: $98.05

$94.48

$134.63

Volume

29,272,893 shs

Average Volume

9,418,368 shs

Market Capitalization

$248.03 billion

P/E Ratio

20.56

Dividend Yield

3.02%

Beta

0.39

First JFK… next Elon?

From Porter & Company | Ad